New Kenya BioVax Institute CEO


Dr. Michael Lusiola has been announced as the new Chief Executive Officer for the Kenya BioVax Institute (KBI).

Dr.Alusiola is expected to assume office immediately from Dr. Rabera Kenyanya who has been the acting CEO since December 2021.

He is a pharmaceutical research and development business executive with over 20years in a multinational setting.

The new CEO attained his graduate and post-graduate academic qualifications from Havard USA  (post-graduate, global public health), Reading UK (post-graduate, business management and administration), Liverpool and Aston UK (post-graduate, evidence-based medicine), and Nairobi Kenya (graduate, pharmacy).

It means he will bring to BioVax a wealth of extraordinary medical-scientific knowledge and expertise as a dynamic and respected leader, having most recently worked as a VP in global clinical development (immunotherapies) at AstraZeneca Pharmaceuticals, UK and USA.  

In a statement by the Kenya BioVax Institute Board of directors, Alusiola’s broad clinical experience and scientific achievements during his tenure at the UK National Health Service (NHS) in senior management and leadership positions over several years, are testament to his capability to steer the organization and deliver its mandate in this complex healthcare environment. 

“We are confident that, after a competitive recruitment process, we have found in Dr. Lusiola, a healthcare and business leader who will head the organization with distinction, scientific innovation, commercial business acumen, and integrity,”  said Mugo Kibati, Chairman of the Board of Directors, Kenya BioVax Institute.

Dr. Lusiola’s appointment comes at a time when The BioVax Institute is undergoing inception, with the primary mandate to manufacture and commercialize specialized human health products and technologies (HPTs), including vaccines, gene therapies, and assistive medical and diagnostic devices.  


Please enter your comment!
Please enter your name here